Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes

World Journal of Gastroenterology

Volumn 9, Issue 9, 2003, Pages 1959-1962

  Yang, Li Qun ^a   Yu, Wei Feng ^a   Cao, Yun Fei ^a   Gong, Bin ^b   Chang, Qing ^b   Yang, Guang Shun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DOPAMINE; EPHEDRINE; FENTANYL; HEMOPROTEIN; ISOENZYME; LIDOCAINE; LIVER ENZYME; PHENOBARBITAL; PROPOFOL; PROTEIN; RANITIDINE; ROCURONIUM; UNCLASSIFIED DRUG; VASOPRESSIN; VECURONIUM; XENOBIOTIC AGENT;

ADULT; ANGIOMA; ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL METABOLISM; COLORIMETRY; DETOXIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL; LIVER CELL CULTURE; LIVER SURGERY; MALE; METABOLIC PARAMETERS; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

EID: 0141829778     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i9.1959     Document Type: Article

References (36)

1. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R. Fujii-Kuriyama Y, Gonzalez FJ Guengerich FP, Gunsalus IC, Johnson EF. The P450 superfamily: Update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991; 10: 1-10
2. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
3. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002; 72: 524-535
4. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51: 281-285
5. Chen TL, Chen TG, Tai YT, Chang HC, Chen RM, Lin CJ, Ueng TH. Propofol inhibits renal cytochrome P450 activity and enflurane defluorinatiion in vitro in hamsters. Can J Anaesth 2000; 47: 680-686
6. Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 1998; 80: 788-795
7. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001; 13: 343-368
8. Morel F, Langouet S, Maheo K, Guillouzo A. The use of primary hepatocyte cultures for the evaluation of chemoprotective agents. Cell Biol Toxicol 1997; 13: 323-329
9. Liddle C, Goodwin BJ, Tapner M. Culture and transfection of mammalian primary hepatocytes and hepatocyte-derived cell lines. J Gastroenterol Hepatol 1998; 13: 855-858
10. Lowry OH, Passonneau JV. Some recent refinements of quantitative histochemical analysis. Curr Probl Clin Biochem 1971; 3: 63-84
11. Hover CG, Kulkarni AP. Lipoxygenase-mediated hydrogen peroxide-dependent N-demethylation of N,N-dimethylaniline and related compounds. Chem Biol Interact 2000; 124: 191-203
12. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, Strom SC. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 1999; 27: 887-894
13. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 1997; 107: 5-16
14. Zhou Q, Yao TW, Zeng S. Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers. World J Gastroenterol 2001; 7: 830-835
15. Guillouzo A, Morel F, Fardel O, Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 1993; 82: 209-219
16. Mode A. Sexually differentiated expression of genes encoding the P4502C cytochromes in rat liver - A model system for studying the action of growth hormone. Reprod Fertil Suppl 1993; 46: 77-86
17. Tenneze L, TarralE, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002; 72: 112-122
18. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12: 465-472
19. Zheng YX, Chan P, Pan ZF, Shi NN, Wang ZX, Pan J, Liang HM, Niu Y, Zhou XR, He FS. Polymorphism of metabolic genes and susceptibility to occupational chronic manganism. Biomarkers 2002; 7: 337-346
20. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470
21. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
22. Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesthesiol Belg 2001; 52: 445-451
23. Gemayel J, Geloen A, Mion F. Propofol-induced cytochrome P450 inhibition: An in vitro and in vivo study in rats. Life Sci 2001; 68: 2957-2965
24. Miller E, Park GR. The effect of oxygen on propofol-induced inhibition of microsomal cytochrome P450 3A4. Anaesthesia 1999; 54: 320-322
25. McKillop D, Wild MJ, Butters CJ, Simcock C. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998; 28: 845-853
26. Chen TL, Wang MJ, Huang CH, Liu CC, Ueng TH. Difference between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450-dependent mono-oxygenases. Br J Anaesth 1995; 75: 462-466
27. Szklarz GD, Halpert JR. Molecular basis of P450 inhibition and activation: Implications for drug development and drug therapy. Drug Metab Dispos 1998; 26: 1179-1184
28. Lehmann A, Boldt J, Thaler E, Piper S, Weisse U. Bispectral index in patients with target-controlled or manually-controlled infusion of propofol. Anesth Analg 2002; 95: 639-644
29. Macquaire V, Cantraine F, Schmartz D, Coussaert E, Barvais L. Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients under-going cardiac surgery. Acta Anaesthesiol Scand 2002; 46: 1010-1016
30. Irwin MG, Hui TW, Milne SE, Kenny GN. Propofol effective concentration 50 and its relationship to bispectral index. Anaesthesia 2002; 57: 242-248
31. Ahonen J, Olkkola KT, Salmenpera M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996; 85: 1246-1252
32. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82: 900-903
33. Nims RW, Prough RA, Jones CR, Stockus DL, Dragnev KH, Thomas PE, Lubet RA. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 1997; 25: 750-756
34. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117: 13-23
35. Ourlin JC, Handschin C, Kaufmann M, Meyer UAA. Link between cholesterol levels and phenobarbital induction of cytochromes P450. Biochem Biophys Res Commun 2002; 291: 378-384
36. Staudinger J, Liu Y, Madan A, Habaeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001; 29: 1467-1472